Acute dystonia induced by the combination of midodrine and perphenazine.
Castrioto
Anna
A
Tambasco
Nicola
N
Rossi
Aroldo
A
Calabresi
Paolo
P
D000208:Acute Disease; D058646:Adrenergic alpha-1 Receptor Agonists; D014150:Antipsychotic Agents / Q000009:adverse effects; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D003865:Major Depressive Disorder / Q000188:drug therapy; D004347:Drug Interactions / Q000502:physiology; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000503:physiopathology*; D004421:Dystonia / Q000139:chemically induced* / Q000503:physiopathology*; D005260:Female; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced / Q000188:drug therapy; D008875:Middle Aged; D008879:Midodrine / Q000009:adverse effects*; D010546:Perphenazine / Q000009:adverse effects*; D018340:Receptors, Adrenergic, alpha-1 / Q000378:metabolism; D014662:Vasoconstrictor Agents / Q000009:adverse effects
D058646:Adrenergic alpha-1 Receptor Agonists; D014150:Antipsychotic Agents; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D018340:Receptors, Adrenergic, alpha-1; D014662:Vasoconstrictor Agents; D008879:Midodrine; D019389:Cytochrome P-450 CYP2D6; D010546:Perphenazine